Direkt zum Inhalt
Merck

An improved method for bonding heparin to intravascular cannulae.

Journal of pharmacological methods (1990-03-01)
A J Freeman, C J Gardner, M G Dodds
ZUSAMMENFASSUNG

The patency of chronically implanted intravascular cannulae is usually limited by thrombus formation at the cannula tip. In the present experiments, methods of improving the antithrombotic properties of the cannulae have been examined using a number of different heparin-bonding treatments. These treatments were evaluated by determining cannula patency in the thoracic aorta of a chronically cannulated rat preparation. Cannulae treated with a heparin-bonding procedure remained patent longer than untreated cannulae. Cannulae treated with tridodecylmethylammonium chloride-heparin-glutaraldehyde remained patent longest (mean patency, 13.3 days compared with 4.0 days in rats with untreated cannulae). This technique provides a simple and effective method of improving the antithrombotic properties of intravascular cannulae by bonding heparin to the lumenal and extralumenal surfaces.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Tridodecylmethylammoniumchlorid, 98%
Sigma-Aldrich
Tridodecylmethylammoniumiodid, 97%
Supelco
Tridodecylmethylammoniumchlorid, Selectophore